Biopharmaceutical start - up TwoXar has raised $ 100 m to develop its AI system , which is aimed at reducing the cost and time needed to identify new drugs . The California - based company uses cloud computing and big data rather than lab - based testing and said its system means drugs will be ready for first - stage testing in weeks rather than years . The series A funding was led by SoftBank Ventures . Andreessen Horowitz and OS Fund also took part . TwoXar TwoXar CEO Andrew Radin said the use of AI in pharmaceuticals had moved from theoretical to practical application and would be a “ major part ” of drug development .
Biopharmaceutical start - up TwoXar has raised $ 100 m to develop its AI system , which is aimed at reducing the cost and time needed to identify new drugs . The California - based company uses cloud computing and big data rather than lab - based testing and said its system means drugs will be ready for first - stage testing in weeks rather than years . The series A funding was led by SoftBank Ventures . Andreessen Horowitz and OS Fund also took part . TwoXar CEO Andrew Radin said the use of AI in pharmaceuticals had moved from theoretical to practical application and would be a “ major part ” of drug development .